Published in Science on March 02, 1990
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol (1991) 4.31
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med (1999) 4.06
Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer (2010) 3.74
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J (1997) 3.34
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 2.90
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer (2006) 2.33
Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med (2009) 2.31
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol (2006) 2.28
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood (2009) 2.15
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A (2006) 2.13
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood (2011) 2.11
Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol (1991) 2.06
Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol (1997) 2.04
An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J (1993) 2.00
The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A (1996) 1.98
Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBO J (1994) 1.94
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol (1996) 1.93
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol (2012) 1.77
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A (2010) 1.75
p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). J Exp Med (2001) 1.73
The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev (1997) 1.72
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther (2008) 1.65
Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med (1999) 1.61
TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. EMBO J (1998) 1.60
Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med (1995) 1.59
Bcr and Raf form a complex in vivo via 14-3-3 proteins. EMBO J (1995) 1.55
Oncogenic gene fusions in epithelial carcinomas. Curr Opin Genet Dev (2009) 1.51
Clonal evolution in hematological malignancies and therapeutic implications. Leukemia (2013) 1.50
Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc Natl Acad Sci U S A (1991) 1.46
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest (1993) 1.43
Analytical methods for inferring functional effects of single base pair substitutions in human cancers. Hum Genet (2009) 1.39
Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. Leuk Res (2009) 1.37
Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A (1999) 1.35
The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation. Mol Cell Biol (1995) 1.34
Tyrosine phosphorylation of p62(Dok) induced by cell adhesion and insulin: possible role in cell migration. EMBO J (1999) 1.31
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood (2009) 1.29
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol (2009) 1.29
Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell (2011) 1.24
Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives. Brief Bioinform (2012) 1.23
BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest (1997) 1.23
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol (2014) 1.22
Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci U S A (1993) 1.22
Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest (2007) 1.21
Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J Biol Chem (2008) 1.21
The aurora kinases in cell cycle and leukemia. Oncogene (2014) 1.20
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct Biol (2009) 1.18
Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood (2010) 1.17
Molecular cloning of Ian4: a BCR/ABL-induced gene that encodes an outer membrane mitochondrial protein with GTP-binding activity. Nucleic Acids Res (2001) 1.17
Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. Clin Cancer Res (2013) 1.16
A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib. Eur J Clin Pharmacol (2016) 1.16
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood (2007) 1.14
Hormone-conditional transformation by fusion proteins of c-Abl and its transforming variants. EMBO J (1993) 1.13
Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J Exp Med (1998) 1.13
A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene (2009) 1.13
FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta (2007) 1.13
Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer (2007) 1.11
Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy. Matrix Biol (2011) 1.10
The CML stem cell: evolution of the progenitor. Cell Cycle (2009) 1.10
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J Cell Mol Med (2008) 1.10
Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma (2008) 1.09
Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc Natl Acad Sci U S A (2000) 1.09
A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene (2006) 1.08
Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line. Mol Cell Biol (1992) 1.08
BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc Natl Acad Sci U S A (1998) 1.07
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep (2015) 1.07
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc Natl Acad Sci U S A (2010) 1.07
ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5. Neoplasia (1999) 1.06
Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. J Exp Med (1994) 1.06
Translocations in epithelial cancers. Biochim Biophys Acta (2009) 1.04
A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. Sci Signal (2013) 1.04
Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract (2014) 1.04
Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells. Leukemia (2010) 1.03
Genomic and proteomic biomarkers for cancer: a multitude of opportunities. Biochim Biophys Acta (2009) 1.03
A fusion protein formed by L-myc and a novel gene in SCLC. EMBO J (1991) 1.03
BCR-ABL prevents c-jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase CbetaII-dependent pathway. Mol Cell Biol (2000) 1.03
A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors. Cancer Res (2010) 1.02
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol (2004) 1.02
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget (2011) 1.02
The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation. Oncogene (2007) 1.00
Tyrosine phosphorylation of p62dok by p210bcr-abl inhibits RasGAP activity. Proc Natl Acad Sci U S A (2000) 1.00
Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer (2010) 1.00
Regulated and constitutive activity by CDC25Mm (GRF), a Ras-specific exchange factor. Mol Cell Biol (1993) 1.00
Clinical significance of microRNAs in chronic and acute human leukemia. Mol Cancer (2016) 0.99
The product of the cbl oncogene forms stable complexes in vivo with endogenous Crk in a tyrosine phosphorylation-dependent manner. Mol Cell Biol (1996) 0.99
Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest (1996) 0.99
Inhibition of the motility and growth of B16F10 mouse melanoma cells by dominant negative mutants of Dok-1. Mol Cell Biol (2001) 0.99
CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. J Clin Invest (2012) 0.99
Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS One (2011) 0.98
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol (2007) 0.98
Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clin Ther (2010) 0.98
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol (2014) 0.97
Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood (2007) 0.97
Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11). BMC Cancer (2004) 0.96
Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. Turk J Haematol (2013) 0.96
Molecular mechanisms of cancer. West J Med (1991) 0.95
P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol (2008) 0.95
Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. Oncotarget (2014) 0.95
BCR/ABL inhibition by an escort/phosphatase fusion protein. Proc Natl Acad Sci U S A (2000) 0.95
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 6.81
Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature (1980) 6.76
Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells. Proc Natl Acad Sci U S A (1978) 6.38
Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell (1980) 5.68
An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell (1984) 4.78
Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci U S A (1988) 4.40
BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol (1991) 4.31
Relationship of retrovirus polyprotein cleavages to virion maturation studied with temperature-sensitive murine leukemia virus mutants. J Virol (1978) 4.06
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
Long-term culture of B lymphocytes and their precursors from murine bone marrow. Proc Natl Acad Sci U S A (1982) 3.74
Differential expression of myc family genes during murine development. Nature (1986) 3.57
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science (1986) 3.53
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med (1997) 3.46
Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50. J Virol (1980) 3.30
c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev (1999) 3.09
In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A (1987) 3.03
Cellular maturation of oncornavirus glycoproteins: topological arrangement of precursor and product forms in cellular membranes. Virology (1977) 3.01
Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol (1985) 2.91
The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol Cell Biol (1989) 2.87
A normal cell protein cross-reactive to the major Abelson murine leukaemia virus gene product. Nature (1979) 2.85
Lethal effect of the Abelson murine leukemia virus transforming gene product. Cell (1981) 2.82
Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med (1994) 2.75
Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science (1996) 2.71
Dominant negative MYC blocks transformation by ABL oncogenes. Cell (1992) 2.64
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 2.61
Retracted Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science (2001) 2.52
Structure of the murine leukemia virus envelope glycoprotein precursor. J Virol (1979) 2.51
Preparation of syngeneic tumor regressor serum reactive with the unique determinants of the Abelson murine leukemia virus-encoded P120 protein at the cell surface. J Virol (1979) 2.50
Leukemia and the disruption of normal hematopoiesis. Cell (1991) 2.43
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res (1999) 2.38
Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J (1998) 2.36
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A (1990) 2.36
BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell (1991) 2.29
A single bone marrow-derived stromal cell type supports the in vitro growth of early lymphoid and myeloid cells. Cell (1987) 2.27
Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family. Science (1994) 2.18
Structural characteristics of some murine RNA tumor viruses studied by lactoperoxidase iodination. Proc Natl Acad Sci U S A (1973) 2.18
A transformation-defective mutant of Abelson murine leukemia virus lacks protein kinase activity. Proc Natl Acad Sci U S A (1980) 2.16
Abelson murine leukemia virus mutants with alterations in the virus-specific P120 molecule. J Virol (1980) 2.16
The viral and cellular forms of the Abelson (abl) oncogene. Adv Virus Res (1988) 2.10
Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity (1996) 2.07
The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell (1991) 2.06
Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase. Proc Natl Acad Sci U S A (1994) 2.04
Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev (1995) 2.02
The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am (1999) 2.00
Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production. J Exp Med (1998) 1.99
A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev (1998) 1.99
Murine B cell lymphopoiesis in long term culture. J Immunol Methods (1984) 1.98
Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc Natl Acad Sci U S A (1986) 1.97
The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science (1987) 1.94
Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc Natl Acad Sci U S A (1985) 1.94
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol (1996) 1.93
Only site-directed antibodies reactive with the highly conserved src-homologous region of the v-abl protein neutralize kinase activity. J Virol (1984) 1.93
Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Mol Cell Biol (1985) 1.92
The Abl interactor proteins localize to sites of actin polymerization at the tips of lamellipodia and filopodia. Curr Biol (2001) 1.91
Vesicular stomatitis virus glycoprotein is necessary for H-2-restricted lysis of infected cells by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1978) 1.88
Abelson murine leukemia virus mutants deficient in kinase activity and lymphoid cell transformation. J Virol (1980) 1.85
Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases. Proc Natl Acad Sci U S A (1997) 1.85
Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement. Proc Natl Acad Sci U S A (1994) 1.83
Abelson virus-infected cells can exhibit restricted in vitro growth and low oncogenic potential. J Virol (1981) 1.80
Mechanism of formation of pseudotypes between vesicular stomatitis virus and murine leukemia virus. Cell (1977) 1.80
Impaired expansion of mouse B cell progenitors lacking Btk. Immunity (1995) 1.79
Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science (1987) 1.76
Genome structure of Abelson murine leukemia virus variants: proviruses in fibroblasts and lymphoid cells. J Virol (1981) 1.73
Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell (1995) 1.73
The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev (2000) 1.71
Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol (1989) 1.67
Regulation of Btk by Src family tyrosine kinases. Mol Cell Biol (1996) 1.66
Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A (2001) 1.65
Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science (1992) 1.62
Polypeptides of Moloney sarcoma-leukemia virions: their resolution and incorporation into extracellular virions. Virology (1974) 1.61
Xid-like phenotypes: a B cell signalosome takes shape. Immunity (2000) 1.60
Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med (1995) 1.59
Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science (1988) 1.59
Transformation of immature lymphoid cells by Abelson murine leukemia virus. Immunol Rev (1979) 1.58
Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity (2001) 1.58
A GDP dissociation inhibitor that serves as a GTPase inhibitor for the Ras-like protein CDC42Hs. Science (1992) 1.58
Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol (1995) 1.57
Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Immunity (1995) 1.56
Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon Fc epsilon RI cross-linking. Mol Cell Biol (1994) 1.54
Redundant and opposing functions of two tyrosine kinases, Btk and Lyn, in mast cell activation. J Immunol (2000) 1.54
Differential complementation of Bcr-Abl point mutants with c-Myc. Science (1994) 1.52
Progression of the transformed phenotype in clonal lines of Abelson virus-infected lymphocytes. Mol Cell Biol (1983) 1.48
Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc Natl Acad Sci U S A (1991) 1.46
Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc Natl Acad Sci U S A (1997) 1.42
Association and activation of Btk and Tec tyrosine kinases by gp130, a signal transducer of the interleukin-6 family of cytokines. Blood (1995) 1.42
Synergism of v-myc and v-Ha-ras in the in vitro neoplastic progression of murine lymphoid cells. Mol Cell Biol (1986) 1.42
Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res (1998) 1.41
Significance of residual leukaemia transcripts after bone marrow transplant for CML. Lancet (1990) 1.40
Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc Natl Acad Sci U S A (2004) 1.39
In vivo tyrosine phosphorylations of the Abelson virus transforming protein are absent in its normal cellular homolog. Cell (1982) 1.39
SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol (1993) 1.38
Btk function in B cell development and response. Semin Immunol (1998) 1.38
Role of Bruton's tyrosine kinase in immunodeficiency. Curr Opin Immunol (1994) 1.37
Long-term culture of murine bone marrow precursors of B lymphocytes. Methods Enzymol (1987) 1.37
Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene (1998) 1.37
Differentiation of cloned populations of immature B cells after transformation with Abelson murine leukemia virus. Cell (1983) 1.36